Work

Feasibility of Low Dose Azacitidine Post T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants in Patients with Myeloid Malignancies At High Risk for Relapse

Year: 2013

Type: article

Abstract: Post transplant relapse remains a main cause of transplant failure and mortality in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Azacitidine, a hypomethylating agent, has been reported to reduce post transplant relapse in these patients after unmodified allogeneic hematopoietic stem cell transplantation (HSCT). There have been no reports of azacitidine use in patients undergoing T cell depleted (TCD) HSCT.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.456

Authors: Roni Tamari, Doris Ponce, Ann A. Jakubowski, Sergio A. Giralt, James Young, Hugo Castro-Malaspina

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650